Bifunctional degraders of galactose-deficient immunoglobulins
AssigneeBiohaven Therapeutics Ltd.
InventorsGene M. Dubowchik, Ada Vaill, Reese M. Caldwell, Brian M. Linhares, David K. Leahy, James Bryson, Lawrence R. Marcin
Life of this patent
Estimating the term…
Abstract
A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.
Claims14
A composition of matter having the chemical formula [AGN101]:
- wherein,
- is a galactose-deficient Immunoglobulin A1 (Gd-IgA1) binding moiety comprising a heavy chain comprising the polypeptide sequences of SEQ ID NO:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11, and a light chain comprising the polypeptide sequences of SEQ ID NO:
- 12, SEQ ID NO:
- 13, and SEQ ID NO:
- 14;
- is a cellular receptor-binding moiety comprising an N-acetyl-D-galactosamine (GalNAc) group;
- and
- L is a linking group,
- a is 1, b is 1, 2, or 3, and c is 1 or 2.
Dependencies are inferred from the claim text.